DRNA
Income statement / Annual
Last year (2020), Dicerna Pharmaceuticals, Inc.'s total revenue was $164.31 M,
an increase of 587.36% from the previous year.
In 2020, Dicerna Pharmaceuticals, Inc.'s net income was -$112.75 M.
See Dicerna Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$164.31 M
|
$23.90 M
|
$6.18 M
|
$2.28 M
|
$295,000.00
|
$184,000.00
|
$0.00
|
$0.00
|
$7.02 M
|
$7.91 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$164.31 M |
$23.90 M |
$6.18 M |
$2.28 M |
$295,000.00 |
$184,000.00 |
$0.00 |
$0.00 |
$7.02 M |
$7.91 M |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
0 |
0 |
1 |
1 |
| Research and Development
Expenses |
$205.38 M
|
$109.34 M
|
$45.71 M
|
$36.98 M
|
$41.69 M
|
$43.97 M
|
$29.45 M
|
$11.56 M
|
$11.57 M
|
$10.71 M
|
| General & Administrative
Expenses |
$72.13 M
|
$42.75 M
|
$21.69 M
|
$25.88 M
|
$18.35 M
|
$19.24 M
|
$15.65 M
|
$5.82 M
|
$4.70 M
|
$4.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$72.13 M
|
$42.75 M
|
$21.69 M
|
$25.88 M
|
$18.35 M
|
$19.24 M
|
$15.65 M
|
$5.82 M
|
$4.70 M
|
$4.82 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$277.52 M |
$152.09 M |
$67.40 M |
$62.86 M |
$60.04 M |
$63.21 M |
$45.10 M |
$17.38 M |
$16.27 M |
$15.52 M |
| Cost And Expenses |
$277.52 M |
$152.09 M |
$67.40 M |
$62.86 M |
$60.04 M |
$63.21 M |
$45.10 M |
$17.38 M |
$16.27 M |
$15.52 M |
| Interest Income |
$6.01 M |
$7.54 M |
$2.10 M |
$539,000.00 |
$235,000.00 |
$188,000.00 |
$63,000.00 |
$4,000.00 |
$2,000.00 |
$3,000.00 |
| Interest Expense |
$20,000.00 |
$3,000.00 |
$603,000.00 |
$0.00 |
$0.00 |
$0.00 |
$199,000.00 |
$952,000.00 |
$1.34 M |
$997,000.00 |
| Depreciation &
Amortization |
$2.22 M
|
$1.25 M
|
$774,000.00
|
$778,000.00
|
$840,000.00
|
$727,000.00
|
$848,000.00
|
$523,000.00
|
$551,000.00
|
$474,000.00
|
| EBITDA |
-$110.51 M
|
-$119.20 M
|
-$87.48 M
|
-$59.27 M
|
-$58.67 M
|
-$62.11 M
|
-$46.89 M
|
-$17.04 M
|
-$8.23 M
|
-$7.09 M
|
| EBITDA Ratio |
-0.67 |
-4.99 |
-14.16 |
-26.03 |
-198.89 |
-337.57 |
0 |
0 |
-1.17 |
-0.9 |
| Operating Income Ratio
|
-0.69
|
-5.36
|
-9.91
|
-26.61
|
-202.54
|
-342.54
|
0
|
0
|
-1.32
|
-0.96
|
| Total Other
Income/Expenses Net |
$461,000.00
|
$7.73 M
|
-$27.63 M
|
$539,000.00
|
$235,000.00
|
$188,000.00
|
-$2.84 M
|
-$1.14 M
|
-$871,000.00
|
-$943,000.00
|
| Income Before Tax |
-$112.75 M |
-$120.46 M |
-$88.85 M |
-$60.05 M |
-$59.51 M |
-$62.84 M |
-$47.94 M |
-$18.52 M |
-$10.12 M |
-$8.56 M |
| Income Before Tax Ratio
|
-0.69
|
-5.04
|
-14.39
|
-26.37
|
-201.74
|
-341.52
|
0
|
0
|
-1.44
|
-1.08
|
| Income Tax Expense |
$481,000.00 |
$7.73 M |
-$27.03 M |
$539,000.00 |
$235,000.00 |
$188,000.00 |
-$2.64 M |
-$188,000.00 |
$471,000.00 |
$54,000.00 |
| Net Income |
-$112.75 M |
-$120.46 M |
-$88.85 M |
-$60.05 M |
-$59.51 M |
-$62.84 M |
-$47.94 M |
-$18.52 M |
-$10.12 M |
-$8.56 M |
| Net Income Ratio |
-0.69 |
-5.04 |
-14.39 |
-26.37 |
-201.74 |
-341.52 |
0 |
0 |
-1.44 |
-1.08 |
| EPS |
-1.51 |
-1.76 |
-1.6 |
-2.9 |
-2.87 |
-3.09 |
-2.98 |
-1.11 |
-4.95 |
-0.11 |
| EPS Diluted |
-1.51 |
-1.76 |
-1.6 |
-2.9 |
-2.87 |
-3.09 |
-2.98 |
-1.11 |
-4.95 |
-0.11 |
| Weighted Average Shares
Out |
$74.52 M
|
$68.43 M
|
$55.62 M
|
$20.72 M
|
$20.72 M
|
$20.32 M
|
$16.07 M
|
$16.63 M
|
$2.05 M
|
$77.91 M
|
| Weighted Average Shares
Out Diluted |
$74.52 M
|
$68.43 M
|
$55.62 M
|
$20.72 M
|
$20.72 M
|
$20.32 M
|
$16.07 M
|
$16.63 M
|
$2.05 M
|
$77.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
